Cargando…

Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors

Patients with lung adenocarcinoma harboring common epidermal growth factor receptor (EGFR) mutations usually have a good response rate (RR) and longer progression-free survival (PFS) to EGFR tyrosine kinase inhibitors (TKIs). However, the treatment efficacy to uncommon EGFR mutations remains controv...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Ming-Ju, Hung, Jen-Yu, Lee, Mei-Hsuan, Kuo, Chia-Yu, Tsai, Yu-Chen, Tsai, Ying-Ming, Liu, Ta-Chih, Yang, Chih-Jen, Huang, Ming-Shyan, Chong, Inn-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266446/
https://www.ncbi.nlm.nih.gov/pubmed/30428509
http://dx.doi.org/10.3390/cancers10110434
_version_ 1783375841016676352
author Tsai, Ming-Ju
Hung, Jen-Yu
Lee, Mei-Hsuan
Kuo, Chia-Yu
Tsai, Yu-Chen
Tsai, Ying-Ming
Liu, Ta-Chih
Yang, Chih-Jen
Huang, Ming-Shyan
Chong, Inn-Wen
author_facet Tsai, Ming-Ju
Hung, Jen-Yu
Lee, Mei-Hsuan
Kuo, Chia-Yu
Tsai, Yu-Chen
Tsai, Ying-Ming
Liu, Ta-Chih
Yang, Chih-Jen
Huang, Ming-Shyan
Chong, Inn-Wen
author_sort Tsai, Ming-Ju
collection PubMed
description Patients with lung adenocarcinoma harboring common epidermal growth factor receptor (EGFR) mutations usually have a good response rate (RR) and longer progression-free survival (PFS) to EGFR tyrosine kinase inhibitors (TKIs). However, the treatment efficacy to uncommon EGFR mutations remains controversial. We, therefore, performed a retrospective study, screening 2958 patients. A total of 67 patients with lung adenocarcinoma harboring uncommon EGFR mutations were enrolled and 57 patients with stage IV diseases receiving a first-line EGFR TKI were included for further analyses. The patients were classified into 27 (47%) “a single sensitizing uncommon mutation”, 7 (12%) “multiple sensitizing mutations”, 5 (9%) “a sensitizing mutation and a resistant uncommon mutation”, and 18 (32%) “other resistant uncommon mutations”. No significant difference was noted in PFS or overall survival (OS) between groups. Patients receiving different first-line EGFR TKIs had similar PFS and OS. The elder patients had a significantly poorer performance status than the younger patients but a significantly longer PFS than the younger patients (median PFS: 10.5 vs. 5.5 months, p = 0.0320). In conclusion, this is the first study to identify that elderly patients with stage IV lung adenocarcinoma harboring uncommon EGFR mutation might have a longer PFS. Large-scale prospective studies are mandatory to prove our findings.
format Online
Article
Text
id pubmed-6266446
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62664462018-12-03 Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors Tsai, Ming-Ju Hung, Jen-Yu Lee, Mei-Hsuan Kuo, Chia-Yu Tsai, Yu-Chen Tsai, Ying-Ming Liu, Ta-Chih Yang, Chih-Jen Huang, Ming-Shyan Chong, Inn-Wen Cancers (Basel) Article Patients with lung adenocarcinoma harboring common epidermal growth factor receptor (EGFR) mutations usually have a good response rate (RR) and longer progression-free survival (PFS) to EGFR tyrosine kinase inhibitors (TKIs). However, the treatment efficacy to uncommon EGFR mutations remains controversial. We, therefore, performed a retrospective study, screening 2958 patients. A total of 67 patients with lung adenocarcinoma harboring uncommon EGFR mutations were enrolled and 57 patients with stage IV diseases receiving a first-line EGFR TKI were included for further analyses. The patients were classified into 27 (47%) “a single sensitizing uncommon mutation”, 7 (12%) “multiple sensitizing mutations”, 5 (9%) “a sensitizing mutation and a resistant uncommon mutation”, and 18 (32%) “other resistant uncommon mutations”. No significant difference was noted in PFS or overall survival (OS) between groups. Patients receiving different first-line EGFR TKIs had similar PFS and OS. The elder patients had a significantly poorer performance status than the younger patients but a significantly longer PFS than the younger patients (median PFS: 10.5 vs. 5.5 months, p = 0.0320). In conclusion, this is the first study to identify that elderly patients with stage IV lung adenocarcinoma harboring uncommon EGFR mutation might have a longer PFS. Large-scale prospective studies are mandatory to prove our findings. MDPI 2018-11-13 /pmc/articles/PMC6266446/ /pubmed/30428509 http://dx.doi.org/10.3390/cancers10110434 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tsai, Ming-Ju
Hung, Jen-Yu
Lee, Mei-Hsuan
Kuo, Chia-Yu
Tsai, Yu-Chen
Tsai, Ying-Ming
Liu, Ta-Chih
Yang, Chih-Jen
Huang, Ming-Shyan
Chong, Inn-Wen
Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
title Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
title_full Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
title_fullStr Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
title_full_unstemmed Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
title_short Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
title_sort better progression-free survival in elderly patients with stage iv lung adenocarcinoma harboring uncommon epidermal growth factor receptor mutations treated with the first-line tyrosine kinase inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266446/
https://www.ncbi.nlm.nih.gov/pubmed/30428509
http://dx.doi.org/10.3390/cancers10110434
work_keys_str_mv AT tsaimingju betterprogressionfreesurvivalinelderlypatientswithstageivlungadenocarcinomaharboringuncommonepidermalgrowthfactorreceptormutationstreatedwiththefirstlinetyrosinekinaseinhibitors
AT hungjenyu betterprogressionfreesurvivalinelderlypatientswithstageivlungadenocarcinomaharboringuncommonepidermalgrowthfactorreceptormutationstreatedwiththefirstlinetyrosinekinaseinhibitors
AT leemeihsuan betterprogressionfreesurvivalinelderlypatientswithstageivlungadenocarcinomaharboringuncommonepidermalgrowthfactorreceptormutationstreatedwiththefirstlinetyrosinekinaseinhibitors
AT kuochiayu betterprogressionfreesurvivalinelderlypatientswithstageivlungadenocarcinomaharboringuncommonepidermalgrowthfactorreceptormutationstreatedwiththefirstlinetyrosinekinaseinhibitors
AT tsaiyuchen betterprogressionfreesurvivalinelderlypatientswithstageivlungadenocarcinomaharboringuncommonepidermalgrowthfactorreceptormutationstreatedwiththefirstlinetyrosinekinaseinhibitors
AT tsaiyingming betterprogressionfreesurvivalinelderlypatientswithstageivlungadenocarcinomaharboringuncommonepidermalgrowthfactorreceptormutationstreatedwiththefirstlinetyrosinekinaseinhibitors
AT liutachih betterprogressionfreesurvivalinelderlypatientswithstageivlungadenocarcinomaharboringuncommonepidermalgrowthfactorreceptormutationstreatedwiththefirstlinetyrosinekinaseinhibitors
AT yangchihjen betterprogressionfreesurvivalinelderlypatientswithstageivlungadenocarcinomaharboringuncommonepidermalgrowthfactorreceptormutationstreatedwiththefirstlinetyrosinekinaseinhibitors
AT huangmingshyan betterprogressionfreesurvivalinelderlypatientswithstageivlungadenocarcinomaharboringuncommonepidermalgrowthfactorreceptormutationstreatedwiththefirstlinetyrosinekinaseinhibitors
AT chonginnwen betterprogressionfreesurvivalinelderlypatientswithstageivlungadenocarcinomaharboringuncommonepidermalgrowthfactorreceptormutationstreatedwiththefirstlinetyrosinekinaseinhibitors